Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279500 · ClinicalTrials.gov registry record · NA
Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa
A NA study, sponsored by Second Sight Medical Products.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00279500: Completed NA study, sponsored by Second Sight Medical Products.
NCT00279500 is a NA study that has completed, run by Second Sight Medical Products. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00279500, a NA study, has completed, sponsored by Second Sight Medical Products.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of the retinal stimulation system by evaluating the data after chronic implantation.
Primary Outcome
All adverse events are collected as a result of chronic electrical stimulation and/or surgical complications.
Interventions
- DEVICE Argus 16 Retinal Stimulation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2002-02-27 |
| Est. Completion | 2014-12-31 |
| Phase | NA |
What the finished NCT00279500 record still lists
NCT00279500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Argus 16 Retinal Stimulation System is the first listed.
NCT00279500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00279500 about?
NCT00279500 is a clinical study titled "Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa". The objective of this study is to evaluate the safety and efficacy of the retinal stimulation system by evaluating the data after chronic implantation.
What is the current status of trial NCT00279500?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2002-02-27. Estimated completion is 2014-12-31.
What interventions are being tested in trial NCT00279500?
The interventions under investigation include: Argus 16 Retinal Stimulation System (DEVICE).
Who is sponsoring clinical trial NCT00279500?
This trial is sponsored by Second Sight Medical Products, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00279500's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI